Brian Stonaker
A5003706260- Cancer Genomics and Diagnostics
- Genetics, Bioinformatics, and Biomedical Research
- Biotechnology and Related Fields
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Global Cancer Incidence and Screening
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Estrogen and related hormone effects
- CRISPR and Genetic Engineering
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Nutrition, Genetics, and Disease
- Inflammatory mediators and NSAID effects
- Cancer-related molecular mechanisms research
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Drug Transport and Resistance Mechanisms
- MicroRNA in disease regulation
- Glutathione Transferases and Polymorphisms
- Lung Cancer Treatments and Mutations
Cornell University
2022-2025
Weill Cornell Medicine
2023-2025
Women of sub-Saharan African descent have disproportionately higher incidence triple-negative breast cancer (TNBC) and TNBC-specific mortality across all populations. Population studies show racial differences in TNBC biology, including prevalence basal-like quadruple-negative subtypes Americans (AA). However, previous investigations relied on self-reported race (SRR) primarily U.S. Due to heterogeneous genetic admixture biological consequences social determinants, the true association...
Abstract Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapeutic strategies. Yet, some targetable genes and pathways essential for tumor cell viability even in the absence of direct alterations. In underrepresented populations, mutational landscape determinants response existing therapies poorly characterized because limited inclusion clinical trials studies. One way reveal is with genetic screens. Most...
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with BRCA1/2 mutations, but other mutations may benefit from PARPi treatment. Another mutation that is present in more cancers than to the TP53 gene. In 2D breast cancer cell lines, mutant p53 (mtp53) proteins tightly associate replicating DNA and (PARP) protein. Combination drug treatment alkylating agent temozolomide talazoparib kills mtp53 expressing grown lines. We evaluated sensitivity combination of plus lung...
<p>PDTOs breast cancer subtype analysis</p>
<p>IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.</p>
<p>List of raw gRNA counts</p>
<p>List of primers and vectors used in this study.</p>
<p>List of inhibitors tested in HTDS alone or combination with gefitinib.</p>
<p>PDTO breast media composition.</p>
<p>Patient clinical information</p>
<div>Abstract<p>Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapeutic strategies. Yet, some targetable genes and pathways essential for tumor cell viability even in the absence of direct alterations. In underrepresented populations, mutational landscape determinants response existing therapies poorly characterized because limited inclusion clinical trials studies. One way reveal is with genetic...
<p>Supplementary Figures 1-7</p>
Abstract Breast cancer (BC), the most diagnosed and leading cause of cancer-related mortality among women worldwide, includes triple-negative breast (TNBC), its aggressive subtype, which is disproportionately prevalent individuals West African ancestry. Our previous studies have demonstrated a correlation between ancestry-specific expression Duffy Antigen Receptor for Chemokines (DARC) TNBC incidence. DARC regulates CC CXC chemokines, maintaining homeostatic chemokine levels. However,...
Abstract Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapy strategies. These usually revealed via next generation sequencing of the tumor tissue. Yet, it is clear some targetable genes and pathways essential for cell viability even in absence direct alterations. This especially important under-represented populations, whose mutational landscape determinants response existing therapies poorly characterized...
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with
Abstract Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapy strategies. These usually revealed via next generation sequencing of the tumor tissue. Yet, it is clear some targetable genes and pathways essential for cell viability even in absence direct alterations. This especially important under-represented populations, whose mutational landscape determinants response existing therapies poorly characterized...
Abstract Background. Despite a recent convergence of breast cancer (BC) incidence rates between African American (AA) and European (EA) women, AA women continue to have ~40% higher mortality rates. BC is heterogeneous collection diseases, where ancestry are disproportionately burdened with the most aggressive subtype BC, triple negative (TNBC). We previously reported that ancestry-specific Duffy-null allele (FY-) risk factor for TNBC diagnoses. FY- promoter variant removes expression Duffy...
Abstract African American women have been observed to higher rates of Triple-Negative Breast Cancer (TNBC) diagnosis, earlier age onset, and mortality from TNBC compared European women. Recent studies shown that tumors exhibit increased immunogenicity. This heightened immune cell infiltration is associated with better prognosis outcomes. The Duffy Antigen Receptor for Chemokines (DARC/ACKR1) has proposed as a driver regulation within breast cancer. association DARC/ACKR1 ancestry stems...
Abstract Breast cancer (BC) is the most frequently diagnosed among women globally and chemotherapy plays a crucial role in its management sub-Saharan Africa. The long-term BC survival rate remains poor due to chemoresistance. Over 80% of currently used drugs are substrates ABC transporter genes, ABCB1, ABCC1 ABCG2. Possessing wild-type genotype alleles these genes reduces intracellular drug accumulation leads poorer treatment outcomes upregulation efflux function. This study therefore...
Significant advances have been made in targeted therapeutics and systemic therapy regimens for breast cancer (BC) treatment over the past decade. Tumour cells can however remain body, leading to locoregional relapse and/or metastasis. Subtypes of BC distinct prognostic effects linked varying risks early metastases, response treatment, overall survival. Most Low- middle-income countries (LMICs) no registries This study comprehensively reviewed, a 3-year retrospective single-centre data female...
Abstract Triple negative breast cancer (TNBC) is the most aggressive molecular subtype of BC, with no targeted therapeutics currently available and poor systemic treatment response among certain patient groups. Cytokines, chemokines adipokines are cell signaling molecules that play significant roles in mediation inflammation/immune tumorigenesis progression. Relative levels these secreted from BC tumor microenvironment may be developed as prognostic liquid biopsy biomarkers. At present, we...
Abstract Background: Breast cancer (BC) is a leading cause of death in Ghana and around the world. Ghanaian women are diagnosed at younger ages with more aggressive Triple Negative BC (TNBC) subtype where West African ancestry associated advanced diagnosis higher mortality rates compared to age-matched European ancestry. Genomic comparisons tumors from show differences frequencies single nucleotide polymorphisms (SNP) copy number variations. These may contribute disparities disease treatment...
<div>Abstract<p>Women of sub-Saharan African descent have disproportionately higher incidence triple-negative breast cancer (TNBC) and TNBC-specific mortality across all populations. Population studies show racial differences in TNBC biology, including prevalence basal-like quadruple-negative subtypes Americans (AA). However, previous investigations relied on self-reported race (SRR) primarily U.S. Due to heterogeneous genetic admixture biological consequences social...
Supplementary Data from African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome Women of Descent
Supplementary Figure from African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome Women of Descent